Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...

Related Keywords

United States , Eiryw Roberts , Neurocrine Biosciences , Neurocrine Biosciences Inc , Linkedin , Takeda Pharmaceutical Company Ltd , Facebook , Twitter , Nasdaq , Chief Medical Officer , Depression Rating , Takeda Pharmaceutical Company ,